Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
doi: 10.1038/s41591-022-02026-4 Summary Keywords obesity, molecular mechanism, semaglutide, liraglutide, weight loss Citation Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramrez P, Paz-Cruz E, Zambrano-Villacres R, Simancas-Racines D and Zambrano AK (2024) Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
Obesity-related cancers identified in the IARC study include endometrial, esophageal, renal cell, gastric, pancreas, colon/rectal, gallbladder, breast, ovarian, and thyroid cancers as well as meningioma, multiple myeloma
There were no deaths considered related to the study treatment.In conclusion, tirzepatide demonstrated superior efficacy compared to titrated insulin degludec in individuals with type 2 diabetes, as evidenced by greater reductions in HbA1c and body weight at week 52 and a lower risk of hypoglycemia
Statistical Analysis Statistical analyses were carried out using SAS version 9.4 (SAS Institute, Cary, NC, USA)
Without your consent, no data will be transferred to YouTube
Serious: Pancreatitis, thyroid problems, and kidney issues (rare)
